Understanding tumor progression is important for developing new treatment methods. To maximize valuable tissue, time and resources, Illumina offers TruSight Tumor 170 (TST170), a next-generation sequencing (NGS) assay designed to cover 170 genes associated with solid tumors. TST170 is an enrichment-based targeted research panel that simultaneously analyzes DNA and RNA.
The content includes 55 genes for fusions and splice variants, 148 SNVs and indels, and 59 amplifications. By harnessing the expertise of recognized authorities in the oncology community, TST170 provides comprehensive coverage of variants most likely to play a role in tumorigenesis.
Product information
For Research Use Only. Not for use in diagnostic procedures.
Company Info:
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other institutions around the globe. For further details please visit www.illumina.com.
Contact Information:
Illumina Cambridge Ltd, Granta Park, Great Abington, Cambridge CB21 6GP, United Kingdom
Telephone: + 44 (0) 1 223 824 800
Contact request: https://emea.illumina.com/forms/contact_request.html
Company website (UK)
QB# 6609
